You are here:
AustLII >>
Databases >>
Federal Court of Australia >>
2009 >>
[2009] FCA 1069
[Database Search]
[Name Search]
[Recent Decisions]
[Noteup]
[Download]
[Help]
Apotex Pty Ltd v Les Laboratoires Servier (No 3) [2009] FCA 1069 (22 September 2009)
Last Updated: 23 September 2009
FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Les Laboratoires Servier
(No 3) [2009] FCA 1069
COSTS – application to amend patent
dismissed – amendments allowable under s 102 of the Patents Act
1990 (Cth) – amendments refused by exercise of discretion under s 105
of the Patents Act 1990 (Cth) – whether costs should be discounted
in favour of party seeking amendment
Apotex Pty Ltd v Les Laboratoires Servier (No
2) [2009] FCA 1019
Gambro Pty Ltd v Fresenius Medical Care South East
Asia Pty Ltd [2000] FCA 407
Wimmera Industrial Minerals Pty Ltd v RGC
Mineral Sands Ltd & Ors, 12 November 1997, Federal Court of Australia,
Sundberg J, unreported
APOTEX PTY LTD (ACN 096 916 148) v LES
LABORATOIRES SERVIER; LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST)
PTY LTD (ACN
004 838 500) v APOTEX PTY LTD (ACN 096 916 148), SYMBION PHARMACY
SERVICES PTY LTD (ACN 000 875 034), CHEM MART PTY LIMITED (ACN
001 235 374),
PHARMACOR LIMITED (ACN 121 020 835), GENEPHARM LIMITED (ARBN 003 854 626) and
SIGMA PHARMACEUTICALS (AUSTRALIA) PTY
LTD (ACN 004 118 594)
NSD 657 of 2008
BENNETT J
22 SEPTEMBER 2009
SYDNEY
IN
THE FEDERAL COURT OF AUSTRALIA
|
|
|
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
|
NSD 657 of 2008
|
|
BETWEEN:
|
APOTEX PTY LTD (ACN 096 916 148)
Appellant
|
|
AND:
|
LES LABORATOIRES SERVIER Respondent
|
|
AND BETWEEN:
|
LES LABORATOIRES SERVIER First Cross-Claimant
SERVIER LABORATORIES (AUST) PTY LTD (ACN 004 838
500) Second Cross-Claimant
|
|
AND:
|
APOTEX PTY LTD (ACN 096 916 148) First
Cross-Respondent
SYMBIION PHARMACY SERVICES PTY LTD (ACN 000 875
034) Second Cross-Respondent
CHEM MART PTY LIMITED (ACN 001 235 374) Third
Cross-Respondent
PHARMACOR LIMITED (ACN 121 020 835) Fourth
Cross-Respondent
GENEPHARM LIMITED (ARBN 003 854 626) Fifth
Cross-Respondent
SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118
594) Sixth Cross-Respondent
|
|
JUDGE:
|
BENNETT J
|
|
DATE:
|
22 SEPTEMBER 2009
|
|
PLACE:
|
SYDNEY
|
REASONS FOR JUDGMENT
- By
an application filed on 2 March 2007, the respondent, Les Laboratoires Servier
(‘Servier’) sought to amend Australian
Patent No 2001276418. The
patent application was filed on 6 July 2001.
- I
found the proposed amendments allowable under s 102 of the Patents Act
1990 (‘the Act’) but, in the exercise of the discretion afforded
by s 105 of the Act, declined to allow the amendments
(Apotex Pty Ltd v
Les Laboratoires Servier (No 2) [2009] FCA 1019). I indicated in my reasons
that I considered it appropriate that Servier pay the applicant’s costs of
the application, which
was dismissed. However, as the parties had not made
submissions on costs, I indicated that that order would be stayed to give the
parties an opportunity to make submissions if they wished to do so.
- Servier
submits that although the ultimate result was in Apotex’s favour and
Apotex is entitled to have costs of the hearing,
it is appropriate to allow a
discount in Servier’s favour to account for Servier’s success in
relation to the allowability
of the amendments under s 102.
- Servier
points out that the issues as to whether or not the amendments were allowable
under s 102 of the Act were complex and
involved evidence from two experts.
In those circumstances, where half of the hearing time concerned those issues,
Servier submits
that Apotex’s entitlement should be discounted by
50%.
- There
are a number of reasons why, in my view, it is appropriate that Servier pay
Apotex’s costs, despite its success in establishing
that the amendments
are allowable under s 102:
- A patentee
seeking to amend a patent is seeking an indulgence of the Court.
- The Court has an
unfettered discretion in the award of costs.
- Where a patentee
seeks to amend its patent, it has frequently been the case that the patentee
pays the opponent’s costs, whether
the amendment application is successful
or not. However, in the exercise of its discretion the Court might refuse costs
or award
reduced costs to a respondent who has made unnecessary or trivial
objections (Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd &
Ors, 12 November 1997, Federal Court of Australia, Sundberg J, unreported).
Where discounts have been granted, it has been in circumstances
such as an
unsuccessful, sustained attack on non-disclosure and where some amendments were
abandoned (Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty
Ltd [2000] FCA 407).
- Apotex’s
conduct in submitting that the amendments were not allowable under s 102
was not unreasonable and the objections
were not trivial (cf
Wimmera).
- One of the
discretionary considerations for the purpose of s 105 was the
characterisation of the invention of the patent. I
decided that the proposed
amended claims, rather than the claims in the unamended patent, encapsulated the
invention. It was for
that reason that the proposed claims were allowable and
that was one of the reasons why the discretion was not exercised in
Servier’s
favour. The two issues were intertwined.
- Importantly,
Apotex was successful and the amendments were not allowed.
- It
follows that, in this case, it is appropriate that costs follow the event.
There is no need to make a further order for costs,
as the stay on the order
previously made will have automatically expired.
I certify that the preceding six (6) numbered
paragraphs are a true copy of the Reasons for Judgment herein of the Honourable
Justice
Bennett.
|
Associate:
Dated: 22 September 2009
Counsel for the
Applicant:
|
|
|
|
|
Counsel for the Respondent:
|
Mr A J Ryan SC
|
Date submissions received:
|
|
|
|
|
Date of Judgment:
|
|
AustLII:
Copyright Policy
|
Disclaimers
|
Privacy Policy
|
Feedback
URL: http://www.austlii.edu.au/au/cases/cth/FCA/2009/1069.html